BDSX Stock Price, Biodesix Inc Quote, Chart

Market Summary

USD1.58+0.02

Market Closed

1.28%

BDSX Stock Price

View Fullscreen

BDSX RSI Chart

BDSX Valuation

Market Cap

178.9M

Price/Earnings (Trailing)

-3.8

Price/Sales (Trailing)

3.26

Price/Free Cashflow

-3.89

BDSX Price/Sales (Trailing)

BDSX Profitability

Return on Equity

855.29%

Return on Assets

-53.96%

Free Cashflow Yield

-25.7%

BDSX Fundamentals

BDSX Revenue

Revenue (TTM)

54.8M

Rev. Growth (Yr)

63.63%

Rev. Growth (Qtr)

1.02%

BDSX Earnings

Earnings (TTM)

-47.1M

Earnings Growth (Yr)

27.21%

Earnings Growth (Qtr)

-48.97%

Breaking Down BDSX Revenue

52 Week Range

1.032.12

(Low)(High)

Last 7 days

0.7%

Last 30 days

24.8%

Last 90 days

5.4%

Trailing 12 Months

28.9%

How does BDSX drawdown profile look like?

BDSX Financial Health

Current Ratio

0.91

BDSX Investor Care

Shares Dilution (1Y)

46.17%

Diluted EPS (TTM)

-0.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	54.8M	0	0	0
2023	40.7M	41.6M	44.0M	49.1M
2022	32.2M	31.3M	35.8M	38.2M
2021	69.3M	77.0M	74.3M	54.5M
2020	29.8M	35.1M	40.3M	45.6M
2019	0	0	0	24.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Biodesix Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 09, 2024	cowie robin harper	sold	-1,449	1.4795	-980	cfo, sec'y & treasurer
May 09, 2024	hutton scott	sold	-5,568	1.4795	-3,764	president & ceo
May 09, 2024	o'kane kieran	sold	-692	1.4795	-468	chief commercial officer
May 09, 2024	vazquez chris	sold	-360	1.4795	-244	chief accounting officer
May 09, 2024	pestano gary anthony	sold	-642	1.4795	-434	chief development officer
May 08, 2024	cowie robin harper	acquired	-	-	3,157	cfo, sec'y & treasurer
May 08, 2024	vazquez chris	acquired	-	-	601	chief accounting officer
May 08, 2024	o'kane kieran	acquired	-	-	1,489	chief commercial officer
May 08, 2024	hutton scott	acquired	-	-	12,212	president & ceo
May 08, 2024	pestano gary anthony	acquired	-	-	1,378	chief development officer

Which funds bought or sold BDSX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Squarepoint Ops LLC	new	-	19,511	19,511	-%
May 15, 2024	Opaleye Management Inc.	added	7.69	-2,846,100	764,560	0.17%
May 15, 2024	Cetera Advisor Networks LLC	unchanged	-	-31,980	111,540	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-12.52	-5,204	11,051	-%
May 15, 2024	Brevan Howard Capital Management LP	new	-	15,051	15,051	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	10.33	-23,949	144,080	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	0.2	-93,310	328,418	0.01%
May 15, 2024	ORACLE INVESTMENT MANAGEMENT INC	reduced	-50.19	-68,726	43,402	0.03%
May 15, 2024	GOLDMAN SACHS GROUP INC	new	-	39,379	39,379	-%
May 15, 2024	BARCLAYS PLC	unchanged	-	-4,000	13,000	-%

Are Funds Buying or Selling BDSX?

Are funds buying BDSX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BDSX

No. of Funds

Unveiling Biodesix Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 13, 2024	perceptive advisors llc	5.6%	6,673,880	SC 13G
Apr 09, 2024	kennedy lawrence t. jr	9.1%	10,304,824	SC 13D/A
Apr 09, 2024	strobeck matthew	4.98%	5,672,000	SC 13D/A
Apr 09, 2024	patience john	6.7%	7,659,411	SC 13D/A
Apr 09, 2024	schuler jack w	27.2%	31,038,797	SC 13D/A
Feb 07, 2024	hirschman orin	3.8%	3,408,946	SC 13G/A
Aug 11, 2023	schuler jack w	32.1%	30,787,721	SC 13D/A
Aug 07, 2023	kennedy lawrence t. jr	10.0%	9,582,783	SC 13D/A
Aug 07, 2023	patience john	7.9%	7,536,698	SC 13D/A
Mar 21, 2023	hirschman orin	7.1%	5,568,901	SC 13G

Recent SEC filings of Biodesix Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	SC 13G	Major Ownership Report
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 10, 2024	4	Insider Trading
May 09, 2024	144	Notice of Insider Sale Intent
May 09, 2024	144	Notice of Insider Sale Intent
May 09, 2024	144	Notice of Insider Sale Intent
May 09, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Biodesix Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.1B	23.7B	10.13%	17.51%	44.54	8.26	-8.94%	-35.91%
A	45.2B	6.7B	12.76%	20.73%	36.58	6.71	-2.81%	-6.58%
IDXX	44.7B	3.7B	10.56%	11.11%	51.58	12	8.57%	23.94%
DGX	15.8B	9.3B	11.84%	7.84%	18.71	1.7	-3.29%	6.68%
NTRA	13.3B	1.2B	20.21%	118.71%	-36.48	11.03	39.26%	33.08%
MEDP	12.2B	2.0B	2.04%	87.82%	38.96	6.2	25.57%	21.62%
CRL	11.6B	4.1B	-3.32%	14.15%	26.37	2.81	0.49%	-11.59%
EXAS	9.6B	2.5B	-18.63%	-33.92%	-39.91	3.78	15.21%	53.51%
MID-CAP
GH	3.2B	603.7M	62.38%	-9.67%	-6.97	5.32	25.21%	30.68%
NEOG	2.9B	929.2M	10.28%	-20.84%	1.9K	3.13	28.93%	111.61%
SMALL-CAP
CDNA	769.8M	275.1M	88.15%	90.09%	-4.2	2.8	-13.93%	-126.97%
ACRS	84.1M	31.1M	-4.10%	-85.92%	-1.09	2.7	0.95%	19.75%
AWH	32.9M	9.2M	-21.45%	-32.59%	-2.23	3.59	11.85%	45.80%
APDN	2.7M	5.5M	708.82%	139.13%	-0.22	0.49	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Biodesix Inc News

Latest updates

Biodesix Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	1.0%	14,818	14,668	13,491	11,872	9,056	9,607	11,107	10,950	6,548	7,224	6,531	11,885	28,866	27,029	9,193	4,239	5,096	4,519	3,942
Operating Expenses	20.0%	25,839	21,538	20,663	22,799	25,429	23,497	21,717	22,576	21,009	18,903	19,622	22,472	34,449	29,682	15,433	9,858	13,518	-	12,970
S&GA Expenses	26.5%	20,556	16,251	15,496	16,651	18,989	16,626	15,114	15,235	14,487	13,558	13,607	11,425	11,927	12,064	7,879	6,834	8,080	-	8,212
R&D Expenses	8.0%	2,040	1,889	1,938	2,910	3,251	3,565	2,970	3,361	3,206	2,852	3,293	3,323	3,321	3,105	2,706	2,107	2,900	-	2,359
Interest Expenses	8.6%	2,529	2,329	2,386	2,430	2,391	2,550	3,039	1,346	1,137	1,496	1,546	815	651	705	2,658	2,784	1,457	-	706
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-49.0%	-13,614	-9,139	-10,949	-13,356	-18,702	-20,338	-13,699	-15,824	-15,586	-13,282	-11,514	-11,402	-6,961	-38,630	-8,845	-8,266	-9,706	-6,525	-9,601
Net Income Margin	19.2%	-0.86*	-1.06*	-1.44*	-1.59*	-1.68*	-1.71*	-1.63*	-1.80*	-1.61*	-0.79*	-0.92*	-0.86*	-	-	-	-	-	-	-
Free Cashflow	-1.8%	-15,545	-15,267	-9,680	-5,480	-15,362	-13,878	-11,108	-9,923	-13,361	-10,727	-8,754	809	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-12.0%	87.00	99.00	87.00	78.00	81.00	93.00	63.00	75.00	62.00	76.00	90.00	102	115	121	47.00	45.00
Current Assets	-28.2%	28.00	40.00	29.00	25.00	35.00	53.00	24.00	35.00	27.00	44.00	56.00	68.00	81.00	86.00	18.00	13.00
Cash Equivalents	-56.0%	12.00	26.00	20.00	17.00	25.00	43.00	15.00	29.00	17.00	33.00	48.00	56.00	55.00	62.00	7.00	5.00
Net PPE	2.5%	29.00	28.00	25.00	19.00	13.00	6.00	4.00	4.00	4.00	4.00	4.00	3.00	3.00	3.00	3.00	2.00
Goodwill	0%	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	15.00	12.00	15.00
Liabilities	-1.9%	93.00	95.00	88.00	85.00	76.00	72.00	66.00	68.00	54.00	56.00	74.00	76.00	79.00	80.00	108	76.00
Current Liabilities	-6.5%	31.00	33.00	33.00	28.00	22.00	23.00	37.00	33.00	30.00	29.00	23.00	21.00	16.00	32.00	57.00	23.00
Shareholder's Equity	-220.1%	-5.50	5.00	-	-	5.00	21.00	-	8.00	8.00	20.00	16.00	26.00	36.00	41.00	-	-
Retained Earnings	-3.2%	-433	-419	-410	-399	-386	-367	-347	-333	-317	-301	-288	-277	-265	-258	-257	-227
Additional Paid-In Capital	0.8%	428	424	409	392	391	388	344	341	325	322	305	303	302	300	3.00	2.00
Shares Outstanding	1.0%	97.00	96.00	88.00	79.00	78.00	78.00	37.00	35.00	31.00	31.00	27.00	3.00	-	-	-	-
Float	-	-	-	-	37.00	-	-	-	34.00	-	-	-	197	-	345	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-24.7%	-15,311	-12,283	-3,838	937	-7,686	-11,948	-10,331	-9,594	-13,099	-10,197	-7,790	1,090	-11,326	-8,756	-3,770	-4,303	-4,537	-	-
Share Based Compensation	144.2%	2,640	1,081	954	1,057	2,281	2,077	1,170	1,368	1,346	1,267	1,386	539	1,752	3,554	100	-	-	-	-
Cashflow From Investing	90.9%	-273	-3,001	-5,883	-6,472	-7,706	-1,987	-815	-380	-352	-641	-1,042	-348	-516	-543	-1,566	-426	-392	-	-
Cashflow From Financing	-96.4%	791	21,728	12,152	-2,330	-2,421	41,848	-2,265	22,133	-2,834	-4,363	396	278	4,951	65,076	9.00	9,626	6,420	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

BDSX Income Statement

2024-03-31

Condensed Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenues	$ 14,818	$ 9,056
Operating expenses:
Direct costs and expenses	3,175	3,169
Research and development	2,040	3,251
Sales, marketing, general and administrative	20,556	18,989
Impairment loss on intangible assets	68	20
Total operating expenses	25,839	25,429
Loss from operations	(11,021)	(16,373)
Other (expense) income:
Interest expense	(2,529)	(2,391)
Change in fair value of warrant liability, net		61
Other (expense) income, net	(64)	1
Total other expense	(2,593)	(2,329)
Net loss	$ (13,614)	$ (18,702)
Net loss per share, basic	$ (0.14)	$ (0.24)
Net loss per share, diluted	$ (0.14)	$ (0.24)
Weighted-average shares outstanding, basic	97,166	77,765
Weighted-average shares outstanding, diluted	97,166	77,765

BDSX Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 11,491	$ 26,284
Accounts receivable, net of allowance for doubtful accounts of $161 and $65	9,893	7,679
Other current assets	7,095	5,720
Total current assets	28,479	39,683
Non‑current assets
Property and equipment, net	28,575	27,867
Intangible assets, net	7,384	7,911
Operating lease right-of-use assets	1,557	1,745
Goodwill	15,031	15,031
Other long-term assets	6,175	6,859
Total non‑current assets	58,722	59,413
Total assets	87,201	99,096
Current liabilities
Accounts payable	3,213	2,929
Accrued liabilities	7,898	7,710
Deferred revenue	313	324
Current portion of operating lease liabilities	272	252
Current portion of contingent consideration	19,195	21,857
Current portion of notes payable	45	51
Other current liabilities	294	293
Total current liabilities	31,230	33,416
Non‑current liabilities
Long‑term notes payable, net of current portion	35,511	35,225
Long-term operating lease liabilities	25,347	25,163
Other long-term liabilities	615	712
Total non‑current liabilities	61,473	61,100
Total liabilities	92,703	94,516
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2024 and 2023) issued and outstanding
Common stock, $0.001 par value, 200,000,000 authorized; 97,159,448 (2024) and 96,235,883 (2023) shares issued and outstanding	97	96
Additional paid‑in capital	427,581	424,050
Accumulated deficit	(433,180)	(419,566)
Total stockholders' (deficit) equity	(5,502)	4,580
Total liabilities and stockholders' equity	$ 87,201	$ 99,096

About Biodesix Inc

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.

CEO	Mr. Scott Hutton
WEBSITE	biodesix.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	245

Biodesix Inc Frequently Asked Questions

What is the ticker symbol for Biodesix Inc? What does BDSX stand for in stocks?

BDSX is the stock ticker symbol of Biodesix Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biodesix Inc (BDSX)?

As of Thu May 16 2024, market cap of Biodesix Inc is 178.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BDSX stock?

You can check BDSX's fair value in chart for subscribers.

What is the fair value of BDSX stock?

You can check BDSX's fair value in chart for subscribers. The fair value of Biodesix Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biodesix Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BDSX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biodesix Inc a good stock to buy?

The fair value guage provides a quick view whether BDSX is over valued or under valued. Whether Biodesix Inc is cheap or expensive depends on the assumptions which impact Biodesix Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BDSX.

What is Biodesix Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, BDSX's PE ratio (Price to Earnings) is -3.8 and Price to Sales (PS) ratio is 3.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BDSX PE ratio will change depending on the future growth rate expectations of investors.